These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35753673)

  • 21. Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).
    Lai TY; Wong RL; Chan WM
    Trans Am Ophthalmol Soc; 2015; 113():T8. PubMed ID: 26755855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
    Liu Y; Li L; Xu G; Wang W
    Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
    Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
    Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative evaluation of damage to retinal capillaries caused by half-dose and half-time photodynamic therapy with optical coherent tomographic angiography.
    Xu F; Lai K; Zhou L; Huang C; Gong Y; Li L; Li C; Zhao H; Lu L; Jin C
    Photodiagnosis Photodyn Ther; 2021 Dec; 36():102477. PubMed ID: 34375777
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Photodynamic therapy for chronic central serous chorioretinopathy and diffuse retinal epitheliopathy].
    Cornut PL; Quaranta-El Maftouhi M; Mauget-Faÿsse M
    J Fr Ophtalmol; 2012 Feb; 35(2):82-7. PubMed ID: 21889817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy.
    van Rijssen TJ; van Dijk EHC; Scholz P; MacLaren RE; Fauser S; Downes SM; Hoyng CB; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2021 Apr; 259(4):905-910. PubMed ID: 33119804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Half-fluence photodynamic therapy in acute central serous chorioretinopathy.
    Smretschnig E; Ansari-Shahrezaei S; Moussa S; Glittenberg C; Krebs I; Binder S
    Retina; 2012; 32(10):2014-9. PubMed ID: 22466482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Photodynamic therapy for treatment of chronic or recurrent central serous chorioretinopathy].
    Li L; Yuan F; Xu GZ; Wang WJ
    Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):106-13. PubMed ID: 22490944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser.
    van Rijssen TJ; van Dijk EHC; Scholz P; Breukink MB; Dijkman G; Peters PJH; Tsonaka R; Keunen JEE; MacLaren RE; Hoyng CB; Downes SM; Fauser S; Boon CJF
    Acta Ophthalmol; 2021 Nov; 99(7):805-811. PubMed ID: 33565230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.
    Zhao M; Zhang F; Chen Y; Dai H; Qu J; Dong C; Kang X; Liu Y; Yang L; Li Y; Zhou P; Pan CT; Zhang L; Liu P; Zhou H; Jiao X; Xiong Y; Tian R; Lu Y; Yu X; Li X
    JAMA Ophthalmol; 2015 Mar; 133(3):333-40. PubMed ID: 25555191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of an additional photodynamic therapy session after multiple failed PDT treatments in chronic central serous chorioretinopathy.
    Moreno-Morillo FJ; Fernández-Vigo JI; Burgos-Blasco B; Moriche-Carretero M; López-Guajardo L; Donate-López J
    Photodiagnosis Photodyn Ther; 2022 Sep; 39():102953. PubMed ID: 35690322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors related to photodynamic therapy for central serous chorioretinopathy.
    Moon JW; Yu HG; Kim TW; Kim HC; Chung H
    Graefes Arch Clin Exp Ophthalmol; 2009 Oct; 247(10):1315-23. PubMed ID: 19421764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term outcomes of half-fluence photodynamic therapy and eplerenone in chronic central serous chorioretinopathy: A comparative study.
    Manayath G; Verghese S; Ranjan R; Agrawal H; Khanna A; Narendran V; Chhablani J
    Eur J Ophthalmol; 2021 Nov; 31(6):3110-3116. PubMed ID: 33508971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors of persistent subretinal fluid after half-dose photodynamic therapy for treatment-naïve central serous chorioretinopathy.
    Li M; Qu J; Liang Z; Tang J; Hu J; Yao Y; Jin E; Li X; Zhao M
    Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2175-2182. PubMed ID: 35024912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
    Maruko I; Iida T; Sugano Y; Ojima A; Ogasawara M; Spaide RF
    Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V; Purtskhvanidze K; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Morphological integrity of the outer retinal layers and visual prognosis in chronic central serous chorioretinopathy after half-dose photodynamic therapy: a qualitative SD-OCT analysis.
    Gobeka HH; Mentes J; Nalcaci S; Oztas Z; Cay Y
    Lasers Med Sci; 2022 Dec; 38(1):9. PubMed ID: 36539551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optical coherent tomographic angiographic pattern of the deep choroidal layer and choriocapillaris after photodynamic therapy for central serous chorioretinopathy.
    Chan SY; Pan CT; Wang Q; Shi XH; Jonas JB; Wei WB
    Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1365-1372. PubMed ID: 31037490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY.
    Lee JH; Lee SC; Kim H; Lee CS
    Retina; 2019 Jan; 39(1):127-133. PubMed ID: 29095358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.